# Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

> **NCT05673590** · PHASE3 · UNKNOWN · sponsor: **Beijing Biostar Pharmaceuticals Co., Ltd.** · enrollment: 612 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Utidelone Injection
- **DRUG:** Docetaxel Injection

## Key facts

- **NCT ID:** NCT05673590
- **Lead sponsor:** Beijing Biostar Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-12
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-12-31
- **Target enrollment:** 612 (ESTIMATED)
- **Last updated:** 2023-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05673590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05673590, "Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05673590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*